GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
GRI Bio, Inc. (GRI)
Company Research
Source: Yahoo! Finance
GRI-0803 systemic lupus erythematosus (SLE) program advancing towards completion of Investigational New Drug (IND) Application enabling studies with IND filing on track for H1 2024 The Company closed a public offering with participation from healthcare focused institutional investors for aggregate gross proceeds of $5.5 million, extending its cash runway into Q3 2024 LA JOLLA, CA, April 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the fiscal year ended December 31, 2023 and provided a corporate update. "Over the past several months we've achieved significant regulatory and clinical milestones while adding $5.5 million to the balance sheet, paving the way for an exciting 2024 marked by key data readouts. Our Phase 2a biomarker study
Show less
Read more
Impact Snapshot
Event Time:
GRI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GRI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GRI alerts
High impacting GRI Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GRI
News
- GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on AutoimmunityGlobeNewswire
- GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar [Yahoo! Finance]Yahoo! Finance
- GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment WebinarGlobeNewswire
- GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea PatentGlobeNewswire
- GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference [Yahoo! Finance]Yahoo! Finance
GRI
Sec Filings
- 4/29/24 - Form PRE
- 4/1/24 - Form 8-K
- 3/28/24 - Form 424B3
- GRI's page on the SEC website